Hepatocellular Carcinoma: A Difficult Cancer to Treat.

Q4 Biochemistry, Genetics and Molecular Biology
Antonella Cusimano, Maurizio Soresi, Giuseppe Montalto, Giuseppa Augello, Maria Rita Emma, Antonina Azzolina, Melchiorre Cervello, Lydia Giannitrapani
{"title":"Hepatocellular Carcinoma: A Difficult Cancer to Treat.","authors":"Antonella Cusimano,&nbsp;Maurizio Soresi,&nbsp;Giuseppe Montalto,&nbsp;Giuseppa Augello,&nbsp;Maria Rita Emma,&nbsp;Antonina Azzolina,&nbsp;Melchiorre Cervello,&nbsp;Lydia Giannitrapani","doi":"10.1615/CritRevOncog.2020036234","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a very peculiar cancer because it presents several molecular alterations linked to the activation of survival and antiapoptotic signal pathways that are protein in form and not easily targetable by even the newest targeted therapies. In addition, it is almost always a consequence of liver cirrhosis, a serious disease condition in which several drugs are often not tolerated. This is why the study of HCC was such a challenge for Professor Natale D'Alessandro, to whom this work is dedicated, during the latter years of his career. The aim of this review is to summarize studies on different molecules involved in the development, progression, and chemoresistance of HCC, topics on which we have focused our research over the last decade. In particular, we have analyzed the role of inflammatory mediators, such as the cyclooxygenase (COX) enzymes, nuclear factor κB (NF-κB), interleukin 6 (IL-6), as well as other important factors, such as Yin Yang 1 (YY1), in HCC. Moreover, we have reviewed some more recent literature on research aimed at identifying druggable targets in HCC as well as candidate agents for its prevention and treatment.</p>","PeriodicalId":35617,"journal":{"name":"Critical Reviews in Oncogenesis","volume":"26 2","pages":"11-25"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Reviews in Oncogenesis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1615/CritRevOncog.2020036234","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 2

Abstract

Hepatocellular carcinoma (HCC) is a very peculiar cancer because it presents several molecular alterations linked to the activation of survival and antiapoptotic signal pathways that are protein in form and not easily targetable by even the newest targeted therapies. In addition, it is almost always a consequence of liver cirrhosis, a serious disease condition in which several drugs are often not tolerated. This is why the study of HCC was such a challenge for Professor Natale D'Alessandro, to whom this work is dedicated, during the latter years of his career. The aim of this review is to summarize studies on different molecules involved in the development, progression, and chemoresistance of HCC, topics on which we have focused our research over the last decade. In particular, we have analyzed the role of inflammatory mediators, such as the cyclooxygenase (COX) enzymes, nuclear factor κB (NF-κB), interleukin 6 (IL-6), as well as other important factors, such as Yin Yang 1 (YY1), in HCC. Moreover, we have reviewed some more recent literature on research aimed at identifying druggable targets in HCC as well as candidate agents for its prevention and treatment.

肝细胞癌:一种难以治疗的癌症。
肝细胞癌(HCC)是一种非常特殊的癌症,因为它呈现出与存活和抗凋亡信号通路激活相关的几种分子改变,这些信号通路以蛋白质形式存在,即使是最新的靶向治疗也不容易靶向。此外,它几乎总是肝硬化的后果,肝硬化是一种严重的疾病,其中几种药物往往不能耐受。这就是为什么对致力于这项工作的Natale D'Alessandro教授来说,HCC的研究在他职业生涯的最后几年是一个巨大的挑战。本综述的目的是总结不同分子参与HCC的发生、进展和化疗耐药的研究,这是我们过去十年来研究的重点。特别是,我们分析了炎症介质,如环氧化酶(COX)酶、核因子κB (NF-κB)、白细胞介素6 (IL-6)以及其他重要因子,如阴阳1 (YY1)在HCC中的作用。此外,我们还回顾了一些最近的研究文献,旨在确定HCC的药物靶点以及预防和治疗HCC的候选药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Critical Reviews in Oncogenesis
Critical Reviews in Oncogenesis Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
1.70
自引率
0.00%
发文量
17
期刊介绍: The journal is dedicated to extensive reviews, minireviews, and special theme issues on topics of current interest in basic and patient-oriented cancer research. The study of systems biology of cancer with its potential for molecular level diagnostics and treatment implies competence across the sciences and an increasing necessity for cancer researchers to understand both the technology and medicine. The journal allows readers to adapt a better understanding of various fields of molecular oncology. We welcome articles on basic biological mechanisms relevant to cancer such as DNA repair, cell cycle, apoptosis, angiogenesis, tumor immunology, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信